Publications by authors named "N Fujioka"
Article Synopsis
- The study aimed to explore changes in choroidal blood flow (CBF) and choroidal thickness (CT) in eyes with non-ischemic branch retinal vein occlusion (BRVO) after treatment with intravitreal aflibercept injections (IVA).
- Conducted on 20 treatment-naive patients, measurements were taken before and after treatment using laser speckle flowgraphy and optical coherence tomography, revealing significant reductions in CBF and CT at specific times post-treatment.
- The findings suggest that aflibercept injections led to decreases in both CBF and CT, which may correlate with improvements in macular edema among the studied BRVO eyes.
Article Synopsis
- This study assesses how choroidal blood flow (CBF) and choroidal thickness (CT) can predict if macular edema will return in patients with a specific type of eye condition (BRVO) after receiving treatment.
- Sixteen patients were treated with an injection and monitored for changes in CBF and CT over a year using specialized imaging techniques.
- Results showed that thicker CT in affected areas initially dropped after one week, while CBF remained steady; however, an imbalance in CBF was linked to how many injections were later needed, suggesting it could help predict recurrence of macular edema.
Lung cancer patient education resources that address barriers to health literacy, improve understanding, and demonstrate improved patient outcomes are limited. Our study aim was to evaluate and report on learner knowledge improvement and intent to implement behavior change, and validate the benefits of the You and Lung Cancer website and YouTube resources. Our study occurred from November 2017 to December 2023.
View Article and Find Full Text PDFBackground: Plinabulin is a GEF-H1 releasing agent with an immune-enhancing function. We report results from a multicenter Phase I/II study (NCT03575793) assessing plinabulin in combination with nivolumab and ipilimumab for the treatment of recurrent SCLC.
Methods: In Phase I, patients were enrolled using a 3 + 3 design to determine dose-limiting toxicities (DLTs) and recommended Phase 2 dose (RP2D).
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (commonly known as NNK) is one of the most prevalent and potent pulmonary carcinogens in tobacco products that increases the human lung cancer risk. Kava has the potential to reduce NNK and tobacco smoke-induced lung cancer risk by enhancing urinary excretion of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL, the major metabolite of NNK) and thus reducing NNK-induced DNA damage. In this study, we quantified -glucuronidated NNAL (NNAL--gluc), -glucuronidated NNAL (NNAL--gluc), and free NNAL in the urine samples collected before and after 1-week kava dietary supplementation.
View Article and Find Full Text PDF